Guidelines and consensus documents

Here you will find guidelines and concensus documents related to hereditary angioedema (HAE).

Early 2022, the European Journal of Allergy and Clinical Immunology published the 2021 revision and update of the international WAO/EAACI guideline for the management of HAE.

The updated guideline reflects consensus among an international panel of 60 HAE experts, and includes 28 recommendations that provide physicians and patients with guidance on important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on-demand treatment, and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breastfeeding women? and (5) How should HAE patients monitor their disease activity, impact, and control?

>> View the international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency.

A comprehensive individualized management plan developed between an expert HAE physician and the patient, in collaboration with local medical providers and emergency departments, can provide patients with the best opportunity to lead a normal life.

>> Download file

WAO Guideline for the Management of Hereditary Angioedema

The outcome of the guideline is to improve diagnosis and management of patients with HAE throughout the world and to help initiate uniform care and availability of therapies to all with the diagnosis no matter where the residence of the individual with HAE exists.

>> Download guide